CLX Quote, Financials, Valuation and Earnings

Kenvue, Inc. has a net margin of 5.74% compared to The Clorox Co.'s net margin of 10.58%. The Clorox Co.'s return on equity of 347.62% beat Kenvue, Inc.'s return on equity of 13.85%.

The Clorox Co. has a consensus price target of $124.59, signalling upside risk potential of 18.54%. On the other hand Kenvue, Inc. has an analysts' consensus of $19.33 which suggests that it could grow by 13.79%. Given that The Clorox Co. has higher upside potential than Kenvue, Inc., analysts believe The Clorox Co. is more attractive than Kenvue, Inc..

The Clorox Co. has a beta of 0.571, which suggesting that the stock is 42.917% less volatile than S&P 500. In comparison Kenvue, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

The Clorox Co. has a quarterly dividend of $1.24 per share corresponding to a yield of 4.68%. Kenvue, Inc. offers a yield of 4.86% to investors and pays a quarterly dividend of $0.21 per share. The Clorox Co. pays 75.19% of its earnings as a dividend. Kenvue, Inc. pays out 150.5% of its earnings as a dividend. The Clorox Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Kenvue, Inc.'s is not.

The Clorox Co. quarterly revenues are $1.4B, which are smaller than Kenvue, Inc. quarterly revenues of $3.8B. The Clorox Co.'s net income of $82M is lower than Kenvue, Inc.'s net income of $398M. Notably, The Clorox Co.'s price-to-earnings ratio is 16.47x while Kenvue, Inc.'s PE ratio is 22.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Clorox Co. is 1.92x versus 2.18x for Kenvue, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Procter & Gamble Co. has a net margin of 5.74% compared to The Clorox Co.'s net margin of 21.36%. The Clorox Co.'s return on equity of 347.62% beat Procter & Gamble Co.'s return on equity of 32.18%.

The Clorox Co. has a consensus price target of $124.59, signalling upside risk potential of 18.54%. On the other hand Procter & Gamble Co. has an analysts' consensus of $169.05 which suggests that it could grow by 16.29%. Given that The Clorox Co. has higher upside potential than Procter & Gamble Co., analysts believe The Clorox Co. is more attractive than Procter & Gamble Co..

The Clorox Co. has a beta of 0.571, which suggesting that the stock is 42.917% less volatile than S&P 500. In comparison Procter & Gamble Co. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.258%.

The Clorox Co. has a quarterly dividend of $1.24 per share corresponding to a yield of 4.68%. Procter & Gamble Co. offers a yield of 2.87% to investors and pays a quarterly dividend of $1.06 per share. The Clorox Co. pays 75.19% of its earnings as a dividend. Procter & Gamble Co. pays out 62.63% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

The Clorox Co. quarterly revenues are $1.4B, which are smaller than Procter & Gamble Co. quarterly revenues of $22.4B. The Clorox Co.'s net income of $82M is lower than Procter & Gamble Co.'s net income of $4.8B. Notably, The Clorox Co.'s price-to-earnings ratio is 16.47x while Procter & Gamble Co.'s PE ratio is 21.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Clorox Co. is 1.92x versus 4.19x for Procter & Gamble Co.. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health Co. has a net margin of 5.74% compared to The Clorox Co.'s net margin of -15.61%. The Clorox Co.'s return on equity of 347.62% beat The Beauty Health Co.'s return on equity of -19.76%.

The Clorox Co. has a consensus price target of $124.59, signalling upside risk potential of 18.54%. On the other hand The Beauty Health Co. has an analysts' consensus of $1.93 which suggests that it could grow by 22.36%. Given that The Beauty Health Co. has higher upside potential than The Clorox Co., analysts believe The Beauty Health Co. is more attractive than The Clorox Co..

The Clorox Co. has a beta of 0.571, which suggesting that the stock is 42.917% less volatile than S&P 500. In comparison The Beauty Health Co. has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.121%.

The Clorox Co. has a quarterly dividend of $1.24 per share corresponding to a yield of 4.68%. The Beauty Health Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Clorox Co. pays 75.19% of its earnings as a dividend. The Beauty Health Co. pays out -- of its earnings as a dividend. The Clorox Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Clorox Co. quarterly revenues are $1.4B, which are larger than The Beauty Health Co. quarterly revenues of $70.7M. The Clorox Co.'s net income of $82M is higher than The Beauty Health Co.'s net income of -$11M. Notably, The Clorox Co.'s price-to-earnings ratio is 16.47x while The Beauty Health Co.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Clorox Co. is 1.92x versus 0.68x for The Beauty Health Co.. Usually stocks with elevated PS ratios are considered overvalued.

Solesence, Inc. has a net margin of 5.74% compared to The Clorox Co.'s net margin of -7.67%. The Clorox Co.'s return on equity of 347.62% beat Solesence, Inc.'s return on equity of 6.62%.

The Clorox Co. has a consensus price target of $124.59, signalling upside risk potential of 18.54%. On the other hand Solesence, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that The Clorox Co. has higher upside potential than Solesence, Inc., analysts believe The Clorox Co. is more attractive than Solesence, Inc..

The Clorox Co. has a beta of 0.571, which suggesting that the stock is 42.917% less volatile than S&P 500. In comparison Solesence, Inc. has a beta of 1.066, suggesting its more volatile than the S&P 500 by 6.59%.

The Clorox Co. has a quarterly dividend of $1.24 per share corresponding to a yield of 4.68%. Solesence, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Clorox Co. pays 75.19% of its earnings as a dividend. Solesence, Inc. pays out -- of its earnings as a dividend. The Clorox Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Clorox Co. quarterly revenues are $1.4B, which are larger than Solesence, Inc. quarterly revenues of $14.6M. The Clorox Co.'s net income of $82M is higher than Solesence, Inc.'s net income of -$1.1M. Notably, The Clorox Co.'s price-to-earnings ratio is 16.47x while Solesence, Inc.'s PE ratio is 155.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Clorox Co. is 1.92x versus 2.49x for Solesence, Inc.. Usually stocks with elevated PS ratios are considered overvalued.